Generalized fractional anisotropy reductions in bundles connecting regions involved in mood regulation and motor function were seen in patients with schizophrenia and bipolar disorder.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia.
Patients with schizophrenia who participated in a telephone intervention problem-solving program were found to have higher rates of medication adherence compared with patients who received routine hospital care for schizophrenia.
Researchers found data to support the benefits of proactively helping patients with schizophrenia quit smoking, including the idea to try to create a substitute that would give patients the benefits that they find by self-medicating with cigarettes, but without the unhealthy adverse effects.
Investigator data shows a higher risk for suicide in patients with schizophrenia who have experienced childhood trauma with an increase in suicidal ideation linked to neglect and depression, while suicide attempts were associated with sexual abuse.
Self-stigma significantly affected patients who are afraid to disclose their disease, which results in increased depression.
Although treatment as usual for psychosis is guideline-congruent and well implemented, there appears to be no added value for adjunct cognitive behavioral therapy for social activation, according to the results of a study from the Netherlands.
Investigators aimed to assess the effect of psychotropic medications, BMI, duration of schizophrenia, number of hospitalizations, and physical activity on the risk for T2D.
Patients receiving treatment with antipsychotic agents would benefit from screening for tardive dyskinesia as these repetitive movements can negatively affect quality of life.
Repeated assessments improved the patients’ ability to assess their own situation and the case workers’ understanding of the patients’ situations.
